Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 7/20 | 0.76 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.70 |
| ▸ | GNA15 | P30679 | 1/20 | 0.58 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.58 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27805773 | 0.88 | HIF1A (0.65) | FFAR1HIF1AGNA15PTGER3FFAR4 | |
| SCHEMBL11421875 | 0.85 | HIF1A (0.72) | FFAR1HIF1AMEN1KMT2AMAPT | |
| SCHEMBL5454790 | 0.84 | FFAR1 (0.74) | FFAR1HIF1AFFAR4TDP1SMN1; SMN2 | |
| SCHEMBL30373777 | 0.82 | HIF1A (0.76) | HIF1ASMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL1134085 | 0.82 | HIF1A (0.76) | HIF1ASMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL229067 | 0.82 | PTGS1 (0.67) | TDP1SMN1; SMN2MEN1KMT2APOLB | |
| SCHEMBL29824310 | 0.82 | PTGS1 (0.67) | TDP1SMN1; SMN2MEN1KMT2APOLB | |
| SCHEMBL30687015 | 0.82 | FFAR1 (0.65) | FFAR1GNA15PTGER3FFAR4TDP1 | |
| SCHEMBL29129868 | 0.82 | FFAR1 (0.65) | FFAR1GNA15PTGER3FFAR4TDP1 | |
| SCHEMBL30687016 | 0.82 | FFAR1 (0.65) | FFAR1GNA15PTGER3FFAR4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010526-A1 | Therapeutic isoquinoline compounds | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
| CN-1608061-A | Therapeutic isoquinoline compounds | ASTRAZENECA AB (SE) | 2005-04-20 | — | — | CN | disclosed |
| EP-1451172-A1 | THERAPEUTIC ISOQUINOLINE COMPOUNDS | AstraZeneca AB (SE) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003037887-A1 | THERAPEUTIC ISOQUINOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010526-A1 | Therapeutic isoquinoline compounds | HTR1B, HTR1D, HTR1A | FFAR1 1385/4885HIF1A 783/4885GNA15 1382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.